Although further validation is required using different cell types and primary leukemic blasts, the present study may suggest the distinct role of GSK-3 isoforms in the regulation of ligands for NK activating receptors and GSK-3α modulation as a potential strategy for enhancing anti-tumor reactivity of NK cells. The gene discussed is SLAMF6; the disease is neoplasm.